SCHEMBL20123043

SCHEMBL20123043

COc1ccc(-c2cc(Cl)cc3c2[nH]c2c(C)nccc23)nc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.40
MAOA P21397 4/20 0.40
CDK2 P24941 4/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
CCNA2 P20248 3/20 0.40
CCNA1 P78396 3/20 0.40
CDK5 Q00535 3/20 0.40
CDK5R1 Q15078 3/20 0.40
CCNT1 O60563 3/20 0.40
CDK9 P50750 3/20 0.40
GSK3B P49841 2/20 0.40
DYRK1B Q9Y463 2/20 0.40
HASPIN Q8TF76 2/20 0.40
DYRK2 Q92630 2/20 0.40
CCNB2 O95067 2/20 0.40
CYP1A2 P05177 2/20 0.40
CDK1 P06493 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664302 1.00 DYRK1A (0.40) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL20123033 0.82 DYRK1A (0.41) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL30664244 0.82 DYRK1A (0.41) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL30664149 0.80 KIT (0.45) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL30664299 0.80 MAOA (0.43) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL20122812 0.80 KIT (0.45) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL20122820 0.80 MAOA (0.43) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL20123059 0.80 HASPIN (0.43) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL30664168 0.80 HASPIN (0.43) DYRK1AMAOACDK2KDM4EALDH1A1
SCHEMBL20122791 0.80 MAOA (0.51) DYRK1AMAOACDK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885MAOA 245/4885CDK2 113/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885MAOA 245/4885CDK2 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.